- In March 2023, Dentsply Sirona highlighted innovations in Bone and Soft Tissue Regeneration at DS World 2023. The company showcased its OSSIX Regenerative Solutions, which utilize GLYMATRIX core technology, designed to optimize bone graft integration and provide long-lasting barrier effects for Guided Bone Regeneration (GBR) and Guided Tissue Regeneration (GTR) procedures. This underscores Dentsply Sirona's continuous efforts to advance biomaterial science for predictable clinical outcomes in implant dentistry
- In December 2023, Geistlich Pharma AG announced the appointment of Diego Gabathuler as its new CEO. This leadership change signals the company's strategic plan for further investment in new products, solutions, and technologies in regenerative medicine, reinforcing its commitment to applying advanced biomaterials to help more people globally. Geistlich is a leading manufacturer of natural bone substitute materials (Geistlich Bio-Oss) and collagen membranes (Geistlich Bio-Gide) used in dental bone grafting
- In March 2023, BioHorizons Camlog participated in the International Osteology Symposium 2023, addressing new approaches on immediacy and soft tissue management. The company presented its comprehensive portfolio of biomaterials and implant systems, offering workshops on bone regeneration and open-healing concepts in modern implant dentistry, highlighting their ongoing contributions to advancements in the field
- In March 2023, Collagen Matrix Inc. rebranded as Regenity Biosciences. This strategic move underscored the company's expanded focus on transforming bioresorbable materials into regenerative solutions for a variety of markets, including dental. With over 71 product lines commercially available worldwide and an accelerating innovation pipeline including new synthetic polymers, Regenity Biosciences is committed to delivering the next generation of regenerative devices for tissue and bone repair
- In April 2024, ZimVie Inc. announced the launch of its Immediate molar dental implant system in the U.S. While primarily an implant system, its focus on simplifying challenging clinical scenarios and shortening treatment times for molar implants indirectly drives the demand for precise bone management, which often involves bone grafting materials. This innovation is designed to enhance primary stability and reduce risks, reflecting the integrated nature of implantology and bone regeneration
